Reni Benjamin

H.C. Wainwright Reiterates Buy On RXi Pharmaceuticals Following Phase 2 Hypertrophic Scarring Trial Update

In a research report published today, H.C.

Ben Mahaney, Editor — December 22, 2014, 1:35 PM EDT

Agenus: Phase 3 Shingles Vaccine Success Raises The Roof For QS-21 Adjuvant, Says H.C. Wainwright

In a research report published Friday, H.C.

Ben Mahaney, Editor — December 19, 2014, 9:11 PM EDT

Can-Fite Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research report issued this morning, H.C.

Ben Mahaney, Editor — December 12, 2014, 11:45 AM EDT

H.C. Wainwright Maintains Buy On OncoSec Following FY1Q15 Update

In a research report sent to investors today, H.C.

Ben Mahaney, Editor — December 11, 2014, 3:21 PM EDT

H.C. Wainwright Maintains Buy On OncoSec Following New Collaboration With The University Of California

In a research report sent to investors today, H.C.

Ben Mahaney, Editor — November 25, 2014, 5:28 PM EDT

RXi Pharmaceuticals Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research note issued today, H.C.

Editor Ben Weinberg — November 18, 2014, 4:52 PM EDT

H.C. Wainwright Reiterates Buy On Keryx Biopharmaceuticals As Several KOLs Chime In

In a research report sent to investors today, H.C.

Jason Cohen Jason Cohen — November 18, 2014, 4:30 PM EDT

H.C. Wainwright Reiterates Buy On Capricor Following 3Q14 Results

In a research note issued today, H.C.

Editor Ben Weinberg — November 13, 2014, 3:55 PM EDT

GenVec Represents An Undervalued Innovator In The Gene Therapy Arena, Says H.C. Wainwright

In a research note published today, H.C.

Editor Ben Weinberg — November 13, 2014, 3:20 PM EDT

Fate Therapeutics Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

H.C.

Editor Ben Weinberg — November 13, 2014, 1:36 PM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts